These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38762464)

  • 1. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.
    Ho WM; Chen CY; Chiang TW; Chuang TJ
    Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Evolution of
    Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
    J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
    Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
    Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
    Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
    Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDH
    Wang S; Li L; Zuo S; Kong L; Wei J; Dong J
    Front Immunol; 2022; 13():869061. PubMed ID: 36248907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
    Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
    Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
    Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
    Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma.
    Riehmer V; Gietzelt J; Beyer U; Hentschel B; Westphal M; Schackert G; Sabel MC; Radlwimmer B; Pietsch T; Reifenberger G; Weller M; Weber RG; Loeffler M;
    Genes Chromosomes Cancer; 2014 Jul; 53(7):589-605. PubMed ID: 24706357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
    Tunthanathip T; Sangkhathat S; Tanvejsilp P; Kanjanapradit K
    Clin Neurol Neurosurg; 2020 Aug; 195():105891. PubMed ID: 32480195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
    Wang PF; Song HW; Cai HQ; Kong LW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2017 Jul; 8(30):50117-50123. PubMed ID: 28223536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme.
    Liu B; Pang B; Liu H; Arakawa Y; Zhang R; Feng B; Zhong P; Murata D; Fan H; Xin T; Zhao G; Liu W; Guo H; Luan L; Xu S; Miyamoto S; Pang Q
    Pathol Res Pract; 2015 Aug; 211(8):596-600. PubMed ID: 26092597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres.
    Yoon SJ; Son HY; Shim JK; Moon JH; Kim EH; Chang JH; Teo WY; Kim SH; Park SW; Huh YM; Kang SG
    J Transl Med; 2020 Dec; 18(1):482. PubMed ID: 33317554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characteristics and clinical features of multifocal glioblastoma.
    Dono A; Wang E; Lopez-Rivera V; Ramesh AV; Tandon N; Ballester LY; Esquenazi Y
    J Neurooncol; 2020 Jun; 148(2):389-397. PubMed ID: 32440969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.